| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Jul, 2026 | Jul, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -62,210 | -37,300 | -28,930 | 0 | 0 |
| Net Income Growth | -66.78% | -28.93% | unch | unch | unch |
Metacrine Inc (MTCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The company's program includes MET409 and MET642 which are in clinical trial. Metacrine Inc. is based in San Diego, United States.
Fiscal Year End Date: 12/31